{{expert needed|date=March 2010}}

{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 409738322
| IUPAC_name =  
| image = Pramlintide sequence.svg
| width = 300
| caption = Golden line indicates [[disulfide]] bond

<!--Clinical data-->
| tradename = Symlin
| Drugs.com = {{drugs.com|monograph|symlin}}
| MedlinePlus = a605031
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = [[Subcutaneous injection|Subcutaneous]]

<!--Pharmacokinetic data-->
| bioavailability = 30 to 40%
| protein_bound = ~60%
| metabolism = [[Kidney|Renal]]
| elimination_half-life = ~48 minutes
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 151126-32-8
| ATC_prefix = A10
| ATC_suffix = BX05
| PubChem = 16132446
| IUPHAR_ligand = 7482
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB01278
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = D3FM8FA78T
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D05595
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201669
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 44241191

<!--Chemical data-->
| C=171 | H=269 | N=51 | O=53 | S=2 
| molecular_weight = 3951.41 g/mol
| smiles            = CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc3ccc(cc3)O)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](Cc5ccccc5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc6cnc[nH]6)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc7ccccc7)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C171H267N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114-73-276-277-74-115(210-140(245)95(173)38-28-29-49-172)158(263)204-108(65-124(179)237)153(258)217-131(85(16)226)164(269)191-84(15)139(244)216-133(87(18)228)168(273)211-114/h22-27,34-37,43-46,67,75-89,95-118,128-135,223-231H,21,28-33,38-42,47-66,68-74,172-173H2,1-20H3,(H2,174,232)(H2,175,233)(H2,176,234)(H2,177,235)(H2,178,236)(H2,179,237)(H2,180,238)(H2,181,241)(H,184,188)(H,186,266)(H,187,246)(H,189,249)(H,190,262)(H,191,269)(H,192,239)(H,193,248)(H,194,270)(H,195,271)(H,196,242)(H,197,247)(H,198,250)(H,199,253)(H,200,252)(H,201,254)(H,202,260)(H,203,259)(H,204,263)(H,205,267)(H,206,272)(H,207,268)(H,208,251)(H,209,261)(H,210,245)(H,211,273)(H,212,256)(H,213,255)(H,214,264)(H,215,243)(H,216,244)(H,217,258)(H,218,257)(H,219,265)(H4,182,183,185)/t81-,82-,83-,84-,85+,86+,87+,88+,89+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128-,129-,130-,131-,132-,133-,134-,135-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = TZIRZGBAFTZREM-MKAGXXMWSA-N
}}

'''Pramlintide''' (trade name '''Symlin''') is an injectable [[amylin]] analogue drug for [[Diabetes mellitus|diabetes]] (both type 1 and 2), developed by [[Amylin Pharmaceuticals]] (now a wholly owned subsidiary of [[AstraZeneca]]).<ref name="pmlive">{{cite web | url=http://www.pmlive.com/pharma_news/astrazeneca_buys_bms_out_of_diabetes_alliance_528427 | title=AstraZeneca buys BMS out of diabetes alliance | date=19 December 2013 | accessdate=16 June 2014 | author=Taylor, Phil}}</ref> Pramlintide is sold as an acetate salt.

==Pharmacology==
Pramlintide is an analogue of [[amylin]], a small peptide [[hormone]] that is released into the [[blood]]stream by the [[Beta cell|β cells]] of the [[pancreas]] along with [[insulin]] after a meal.<ref name="pmid17619527">{{cite journal |author=Jones MC |title=Therapies for diabetes: pramlintide and exenatide |journal=American Family Physician |volume=75 |issue=12 |pages=1831–5 |year=2007 |pmid=17619527 |doi=|url=http://www.aafp.org/afp/2007/0615/p1831.pdf|format=pdf}}</ref>  Like insulin, amylin is completely absent in individuals with Type I diabetes.<ref name="EdelmanMaier2008">{{cite journal|last1=Edelman|first1=Steve|last2=Maier|first2=Holly|last3=Wilhelm|first3=Ken|title=Pramlintide in the Treatment of Diabetes Mellitus|journal=BioDrugs|volume=22|issue=6|year=2008|pages=375–386|issn=1173-8804|doi=10.2165/0063030-200822060-00004}}</ref>

In synergy with endogenous amylin, pramlintide aids in the regulation of blood [[glucose]] by slowing [[Stomach|gastric emptying]], promoting [[satiety]] via [[hypothalamus|hypothalamic]] receptors (different receptors than for [[Glucagon-like peptide 1|GLP-1]]), and inhibiting inappropriate secretion of [[glucagon]], a catabolic hormone that opposes the effects of insulin and amylin. Pramlintide also has effects in raising the acute first-phase insulin response threshold following a meal.

Both a reduction in [[glycated hemoglobin]] and weight loss have been shown in insulin-treated patients with type 2 diabetes taking pramlintide as an adjunctive therapy.<ref name="HollanderMaggs2004">{{cite journal|last1=Hollander|first1=Priscilla|last2=Maggs|first2=David G.|last3=Ruggles|first3=James A.|last4=Fineman|first4=Mark|last5=Shen|first5=Larry|last6=Kolterman|first6=Orville G.|last7=Weyer|first7=Christian|title=Effect of Pramlintide on Weight in Overweight and Obese Insulin-Treated Type 2 Diabetes Patients| journal=Obesity| volume=12| issue=4| year=2004| pages=661–668| issn=1930-7381|doi=10.1038/oby.2004.76|url=http://www.nature.com/oby/journal/v12/n4/pdf/oby200476a.pdf|format=pdf}}</ref>

==Approval==
Pramlintide has been approved by the FDA, for use by type 1 and type 2 diabetic patients who use insulin.<ref name="pmid16330288">{{cite journal |vauthors=Ryan GJ, Jobe LJ, Martin R |title=Pramlintide in the treatment of type 1 and type 2 diabetes mellitus |journal=Clinical therapeutics |volume=27 |issue=10 |pages=1500–12 |year=2005 |pmid=16330288 |doi=10.1016/j.clinthera.2005.10.009}}</ref>  Pramlintide allows patients to use less insulin, lowers average blood sugar levels, and substantially reduces what otherwise would be a large unhealthy rise in blood sugar that occurs in diabetics right after eating.

Apart from insulin analogs, pramlintide is the only drug approved by the FDA to lower blood sugar in type 1 diabetics since insulin in the early 1920s.{{citation needed|date=March 2017}}

==Design and structure==
{{refimprove section|date=March 2017}}
Since native human amylin is highly [[amyloid]]ogenic and potentially toxic, the strategy for designing pramlintide was to substitute residues from rat amylin, which is less amyloidogenic although not completely
<ref>{{cite journal|authors= Palmieri, Leonardo C; Melo-Ferreira, Bruno; Braga, Carolina A; Fontes, Giselle N; Mattos, Luana J; Lima, Luis Mauricio|title=Stepwise oligomerization of murine amylin and assembly of amyloid fibrils|journal=Bioph Chem|date=2013|volume=181|pages=135–144|doi=10.1016/j.bpc.2013.07.013|pmid=23974296|url=http://www.sciencedirect.com/science/article/pii/S0301462213001336}}</ref><ref>{{cite journal |authors=Erthal, Luiza C; Marques, Adriana F; Almeida, Fábio C; Melo, Gustavo L; Carvalho, Camila M; Palmieri, Leonardo C; Cabral, Kátia M; Fontes, Giselle N; Lima, Luis Mauricio |title=Regulation of the assembly and amyloid aggregation of murine amylin by zinc |journal=Biophys. Chem. |volume=218 |pages=58–70 |year=2016 |pmid=27693831 |doi=10.1016/j.bpc.2016.09.008|url=http://www.sciencedirect.com/science/article/pii/S030146221630182X}}</ref> (but would presumably retain clinical activity). Proline residues are known to be structure-breaking residues, so these were directly grafted into the human sequence. Despite its enhanced stability compared to human amylin, pramlintide is still able to organize into amyloid material.<ref>{{cite journal |authors= da Silva, Dayana C; Fontes, Giselle N; Erthal, Luiza C; Lima, Luis Mauricio. |title=Amyloidogenesis of the amylin analogue pramlintide. |journal=Biophys. Chem. |volume=219 | pages=1–8 |year=2016 |pmid=27665170 |doi=10.1016/j.bpc.2016.09.007|url=http://www.sciencedirect.com/science/article/pii/S0301462216301673}}</ref>

Amino acid sequences:

{| class="wikitable"
|-
| Pramlintide || <code>KCNTATCATQRLANFLV'''H'''SSNN'''F'''G'''PI'''L'''PP'''TNVGSNTY-(NH<sub>2</sub>)</code>
|-
| Amylin || <code>KCNTATCATQRLANFLV'''H'''SSNN'''F'''G'''AI'''L'''SS'''TNVGSNTY-(NH<sub>2</sub>)</code>
|-
| Rat amylin || <code>KCNTATCATQRLANFLV'''R'''SSNN'''L'''G'''PV'''L'''PP'''TNVGSNTY-(NH<sub>2</sub>)</code>
|}

Pramlintide as protein is (positively charged).

==References==
<references/>

==External links==
*[http://www.symlin.com www.symlin.com] - product website
*[http://www.amylin.com/pipeline/symlin.cfm www.amylin.com] - Symlin page on the Amylin Pharmaceuticals website

{{Oral hypoglycemics and insulin analogs}}
{{Neuropeptidergics}}

[[Category:Anti-diabetic drugs]]
[[Category:Diabetes]]
[[Category:Human proteins]]
[[Category:Recombinant proteins]]
[[Category:Peptide hormones]]